Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00372996 · ClinicalTrials.gov registry record · Phase 2
Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer
A Phase 2 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 2
- Development phase
- 219
- Enrollment target
NCT00372996 is a Phase 2 study that was terminated before completion, run by Pfizer. The registered enrollment target is 219 participants.
The verdict
NCT00372996, a Phase 2 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 219 participants
- Enrollment target
Study Summary
To test the efficacy of CP-751,871 combined with exemestane in the treatment of postmenopausal patients with hormone positive advanced breast cancer
Interventions
- DRUG Fulvestrant
- DRUG exemestane
- DRUG CP-751,871
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 219 participants |
| Start Date | 2007-02 |
| Est. Completion | 2014-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00372996
The ClinicalTrials.gov registry entry for NCT00372996 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 219 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Fulvestrant is the first listed.
NCT00372996 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00372996 about?
NCT00372996 is a clinical study titled "Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer". To test the efficacy of CP-751,871 combined with exemestane in the treatment of postmenopausal patients with hormone positive advanced breast cancer
What is the current status of trial NCT00372996?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 219 participants. The study started on 2007-02. Estimated completion is 2014-06.
What interventions are being tested in trial NCT00372996?
The interventions under investigation include: Fulvestrant (DRUG), exemestane (DRUG), CP-751,871 (DRUG).
Who is sponsoring clinical trial NCT00372996?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.